

ABSTRACT OF THE DISCLOSURE

Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.

09879451.061201
T02T90" T946/860

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 16/24, 16/46, 17/02, C07H 15/12, G01N 33/53, C12P 21/08, C12N 5/10, 5/20, 15/13, A61K 39/395	A1	(11) International Publication Number: WO 95/07301 (43) International Publication Date: 16 March 1995 (16.03.95)
(21) International Application Number: PCT/US94/10308 (22) International Filing Date: 7 September 1994 (07.09.94) (30) Priority Data: 08/117,366 7 September 1993 (07.09.93) US 08/136,783 14 October 1993 (14.10.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/136,783 (CIP) Filed on 14 October 1993 (14.10.93) (71) Applicants (for all designated States except US): SMITHK- LINE BEECHAM CORPORATION [US/US]; Corporate In- tellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). SMITHK- LINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford TW8 9BD (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HOLMES, Stephen, Dud- ley [GB/GB]; Yew Tree Bottom Road, Epsom, Surrey KT15 5XQ (GB). GROSS, Mitchell, Stuart [US/US]; 667 Pugh		(74) Agents: SUTTON, Jeffrey, A. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: RECOMBINANT IL4 ANTIBODIES USEFUL IN TREATMENT OF IL4 MEDIATED DISORDERS (57) Abstract Chimeric and humanized IL4 MAbs derived from high affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.		